Compare EVGOW & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVGOW | CMMB |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | Israel |
| Employees | 376 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 13.0M |
| IPO Year | N/A | 2023 |
| Metric | EVGOW | CMMB |
|---|---|---|
| Price | $0.01 | $1.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 365.6K | 49.9K |
| Earning Date | 03-07-2025 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $239,306,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $38.00 |
| Revenue Growth | ★ 73.08 | N/A |
| 52 Week Low | $0.00 | $0.87 |
| 52 Week High | $0.27 | $3.86 |
| Indicator | EVGOW | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 39.19 | 39.66 |
| Support Level | N/A | $1.48 |
| Resistance Level | $0.03 | $1.89 |
| Average True Range (ATR) | 0.01 | 0.17 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 3.83 | 4.60 |
EVgo Inc is an EV fast charging provider. The company deploys charging infrastructure by partnering with retailers, grocery stores, restaurants, gas stations, rideshare operators, and autonomous vehicle companies across the U.S., and serves the EV commercial segment by deploying fleet-charging solutions for light-duty EV fleets at depot locations, off-site charging hubs, or through its public network. It also owns PlugShare, a platform for EV drivers to locate public charging stations, plan trips and share charging experiences, which also provides charging location data licensing, infrastructure analysis, and EV driver research. It also derives revenue from the sale of regulatory credits earned from participation in LCFS programs and other carbon or emissions trading schemes in the U.S.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.